Literature DB >> 7777498

Structural variety of arginine-rich RNA-binding peptides.

R Tan1, A D Frankel.   

Abstract

Arginine-rich domains are used by a variety of RNA-binding proteins to recognize specific RNA hairpins. It has been shown previously that a 17-aa arginine-rich peptide from the human immunodeficiency virus Rev protein binds specifically to its RNA site when the peptide is in an alpha-helical conformation. Here we show that related peptides from splicing factors, viral coat proteins, and bacteriophage antiterminators (the N proteins) also have propensities to form alpha-helices and that the N peptides require helical conformations to bind to their cognate RNAs. In contrast, introducing proline mutations into the arginine-rich domain of the human immunodeficiency virus Tat protein abolishes its potential to form an alpha-helix but does not affect RNA-binding affinity in vitro or in vivo. Based on results from several peptide-RNA model systems, we suggest that helical peptides may be used to recognize RNA structures having particularly wide major grooves, such as those found near loops or large bulges, and that nonhelical or extended peptides may be used to recognize less accessible grooves.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7777498      PMCID: PMC41678          DOI: 10.1073/pnas.92.12.5282

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  40 in total

1.  Effects of all single base substitutions in the loop of boxB on antitermination of transcription by bacteriophage lambda's N protein.

Authors:  J H Doelling; N C Franklin
Journal:  Nucleic Acids Res       Date:  1989-07-25       Impact factor: 16.971

2.  Analysis of arginine-rich peptides from the HIV Tat protein reveals unusual features of RNA-protein recognition.

Authors:  B J Calnan; S Biancalana; D Hudson; A D Frankel
Journal:  Genes Dev       Date:  1991-02       Impact factor: 11.361

3.  Activity of synthetic peptides from the Tat protein of human immunodeficiency virus type 1.

Authors:  A D Frankel; S Biancalana; D Hudson
Journal:  Proc Natl Acad Sci U S A       Date:  1989-10       Impact factor: 11.205

4.  Transactivation induced by human T-lymphotropic virus type III (HTLV III) maps to a viral sequence encoding 58 amino acids and lacks tissue specificity.

Authors:  L J Seigel; L Ratner; S F Josephs; D Derse; M B Feinberg; G R Reyes; S J O'Brien; F Wong-Staal
Journal:  Virology       Date:  1986-01-15       Impact factor: 3.616

5.  Synthesis of small RNAs using T7 RNA polymerase.

Authors:  J F Milligan; O C Uhlenbeck
Journal:  Methods Enzymol       Date:  1989       Impact factor: 1.600

6.  Structure of E. coli glutaminyl-tRNA synthetase complexed with tRNA(Gln) and ATP at 2.8 A resolution.

Authors:  M A Rould; J J Perona; D Söll; T A Steitz
Journal:  Science       Date:  1989-12-01       Impact factor: 47.728

7.  Class II aminoacyl transfer RNA synthetases: crystal structure of yeast aspartyl-tRNA synthetase complexed with tRNA(Asp).

Authors:  M Ruff; S Krishnaswamy; M Boeglin; A Poterszman; A Mitschler; A Podjarny; B Rees; J C Thierry; D Moras
Journal:  Science       Date:  1991-06-21       Impact factor: 47.728

8.  Arginine-mediated RNA recognition: the arginine fork.

Authors:  B J Calnan; B Tidor; S Biancalana; D Hudson; A D Frankel
Journal:  Science       Date:  1991-05-24       Impact factor: 47.728

9.  Effects of deletions in the N-terminal basic arm of brome mosaic virus coat protein on RNA packaging and systemic infection.

Authors:  R Sacher; P Ahlquist
Journal:  J Virol       Date:  1989-11       Impact factor: 5.103

10.  The molecular characterization of PRP6 and PRP9 yeast genes reveals a new cysteine/histidine motif common to several splicing factors.

Authors:  P Legrain; A Choulika
Journal:  EMBO J       Date:  1990-09       Impact factor: 11.598

View more
  64 in total

1.  Mapping of the RNA recognition site of Escherichia coli ribosomal protein S7.

Authors:  F Robert; M Gagnon; D Sans; S Michnick; L Brakier-Gingras
Journal:  RNA       Date:  2000-11       Impact factor: 4.942

2.  Large libraries reveal diverse solutions to an RNA recognition problem.

Authors:  J E Barrick; T T Takahashi; J Ren; T Xia; R W Roberts
Journal:  Proc Natl Acad Sci U S A       Date:  2001-10-23       Impact factor: 11.205

3.  Design and development of a catalytic ribonucleoprotein.

Authors:  S Atsumi; Y Ikawa; H Shiraishi; T Inoue
Journal:  EMBO J       Date:  2001-10-01       Impact factor: 11.598

4.  Structural mimicry in the phage phi21 N peptide-boxB RNA complex.

Authors:  Christopher D Cilley; James R Williamson
Journal:  RNA       Date:  2003-06       Impact factor: 4.942

5.  In vitro selection of ribozymes dependent on peptides for activity.

Authors:  Michael P Robertson; Scott M Knudsen; Andrew D Ellington
Journal:  RNA       Date:  2004-01       Impact factor: 4.942

6.  Selection of RRE RNA binding peptides using a kanamycin antitermination assay.

Authors:  Hadas Peled-Zehavi; Satoru Horiya; Chandreyee Das; Kazuo Harada; Alan D Frankel
Journal:  RNA       Date:  2003-02       Impact factor: 4.942

7.  The arginine-rich RNA-binding motif of HIV-1 Rev is intrinsically disordered and folds upon RRE binding.

Authors:  Fabio Casu; Brendan M Duggan; Mirko Hennig
Journal:  Biophys J       Date:  2013-08-20       Impact factor: 4.033

Review 8.  Recognition modes of RNA tetraloops and tetraloop-like motifs by RNA-binding proteins.

Authors:  Roopa Thapar; Andria P Denmon; Edward P Nikonowicz
Journal:  Wiley Interdiscip Rev RNA       Date:  2013-10-03       Impact factor: 9.957

9.  Correction of mutations within the cystic fibrosis transmembrane conductance regulator by site-directed RNA editing.

Authors:  Maria Fernanda Montiel-Gonzalez; Isabel Vallecillo-Viejo; Guillermo A Yudowski; Joshua J C Rosenthal
Journal:  Proc Natl Acad Sci U S A       Date:  2013-10-09       Impact factor: 11.205

10.  Nuclear import of APOBEC3F-labeled HIV-1 preintegration complexes.

Authors:  Ryan C Burdick; Wei-Shau Hu; Vinay K Pathak
Journal:  Proc Natl Acad Sci U S A       Date:  2013-11-18       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.